OncoSec Medical Enters Sponsored Research Agreement with Old Dominion University for Combination Study in Melanoma

Study to Evaluate the Effects of ImmunoPulse in Combination with Anti-CTLA4, Anti-PD1 and Anti-PDL-1 Therapies

 SAN DIEGO – June 11, 2013 – OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, signed a Sponsored Research Agreement (SRA) with Old Dominion University (ODU) and the Frank Reidy Research Center for Bioelectrics. Under the agreement, OncoSec and the University will collaborate on nonclinical research focused on developing new technology related to electroporation and delivery of different agents into solid tumors by electroporation.

The first research experiment under this SRA will evaluate the effects of ImmunoPulse in combination with Anti-CTLA4, Anti-PD1 and Anti-PDL-1 in a melanoma mouse model. The study will commence this month and data from these experiments will be announced at a later date.

“Although results from ongoing Phase 2 studies have demonstrated ImmunoPulse is a potentially effective monotherapy for the treatment of skin cancers such as melanoma and Merkel cell carcinoma, OncoSec continues to evaluate opportunities where ImmunoPulse can be combined with other therapies to either improve its effectiveness or broaden the use of ImmunoPulse into other indications,” said Punit Dhillon, President and CEO of OncoSec Medical.

Mr. Dhillon continued, “The signing of this research agreement with ODU enables the company to determine which combination approaches are most effective and will help guide the company in the development of ImmunoPulse for its melanoma program and other solid tumor malignancies. The recent data announced at ASCO demonstrating the benefit of combining Ipilimumab (Anti-CTLA-4) with Nivolimumab (Anti-PD-1) for the treatment of advanced-stage melanoma, provides further support toward OncoSec’s efforts to expand the use of ImmunoPulse through the evaluation of different combination approaches to assess synergistic effects.”

The principal investigator of the study will be Dr. Richard Heller, one of the world’s leading pioneers in electroporation and gene delivery. Dr. Heller sits on OncoSec’s Scientific Advisory Board and has more than 25 years of experience in evaluating effects of electric pulses on biological systems.

Dr. Heller said, “We are excited to be collaborating with OncoSec. The combination of immune modulating agents to treat aggressive cancers like melanoma will further the scientific community’s understanding of these therapies. ImmunoPulse has continued to demonstrate a clear safety profile with promising clinical results, so we are looking forward to learn about the benefits of these new combinations.”

About Frank Reidy Research Center for Bioelectrics

The mission of the Center is to increase scientific knowledge and understanding of the interaction of electromagnetic fields and ionized gases with biological cells and to apply this knowledge to the development of medical diagnostics, therapeutics, and environmental decontamination. The objectives of the Center are to perform leading edge interdisciplinary and multi-institutional research, recruit top faculty and exceptional graduate students, support regional, national and international programs, and to increase external funding and institutional visibility.

 

FOR IMMEDIATE RELEASE

SAN DIEGO – April 18, 2013 – OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, is one of the first to partner with Smart Patients: a new online community where patients with life-threatening conditions who are looking for or participating in clinical trials can share their feedback and experiences. Google’s former Chief Health Strategist, Roni Zeiger, will be speaking at the TEDMED conference in Washington, D.C. today to unveil the new website.

OncoSec is working with Smart Patients to create a community for Merkel cell carcinoma (MCC) patients. MCC is an extremely rare and aggressive form of skin cancer that currently has no approved therapies. OncoSec is conducting the only active Phase II immunotherapy trial that is focused specifically on the disease. The Smart Patients partnership will provide valuable insight from patients to help improve clinical trial design and enable better collaboration with patients.

“We’re excited to be working with Dr. Zeiger, and to be a part of creating this valuable resource for the Merkel cell community,” said OncoSec’s CEO, Punit Dhillon. “One of the most frightening parts of being diagnosed with a rare disease like MCC is a lack of information about the condition and treatment options. Smart Patients is providing an important resource to help patients connect and learn from each other.”

Roni Zeiger, co-founder and CEO of Smart Patients, noted, “Together with OncoSec, we will be able to gain a better understanding of MCC from a patient perspective, and help design more patient-centered trials that will make scientific breakthroughs for this disease available sooner.”

About Smart Patients

Smart Patients is an online community for cancer patients and caregivers. The community includes a clinical trial search engine that presents trial data from ClinicalTrials.gov in a patient-friendly format. The community platform has been in private beta testing since January 2013 and is now open to all cancer patients and caregivers. To learn more, please visit us at www.smartpatients.com.

 

SAN DIEGO – March 18, 2013 — OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced Dr. Adil Daud, chair of OncoSec’s Melanoma Advisory Board, will present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting at the Hilton New York Hotel on Friday, March 22 at 2:25 PM ET.

Dr. Daud will provide a presentation titled “Gene Therapy in Melanoma with pIL-12” and will review previously announced Phase I and II data from the ImmunoPulse clinical program in melanoma. More information can be found here: http://www.hemonctodaymelanoma.com/agenda.aspx#Fri

About the HemOnc Today Melanoma Meeting

 The HemOnc Today Melanoma Conference will feature more than 20 renowned speakers and 200 colleagues who will discuss pertinent aspects of management and biology of melanoma and other cutaneous malignancies.

The two-day event will feature expert perspectives from renowned specialists who have advanced expertise in oncology, dermatology and cutaneous malignancies and will explain how you can apply the new research and advances presented to your own patients and practice.

 

SAN DIEGO – February 6, 2013 — OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present at the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City, on Tuesday, February 12th at 3:00PM Eastern Time.

 

ABOUT THE BIO CEO & INVESTOR CONFERENCE

The 15th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies.  This year’s conference will feature corporate presentations from more than 150 leading biotechnology and pharmaceutical companies, five Fireside Chats with industry leaders, three Therapeutic Workshops and five Business Roundtables all drawing from seasoned industry executives and analysts. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. To find out more information on the event, visit http://www.bio.org/events/conferences/bio-ceo-investor-conference

Presentations on December 6 to Cover ImmunoPulse Therapy and Phase II Study of Melanoma Patients 

SAN DIEGO – December 04, 2012 — OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced it will be presenting at the DNA Vaccines 2012 Conference at the Loews Coronado Bay Resort in San Diego, California. OncoSec is a Silver Sponsor of the conference.

The Company will conduct two presentations within the Cancer Immune Therapy Track on Thursday, December 6:

From 11:30 AM-12:00 PM PT, Richard Heller, Ph.D., director of the Frank Reidy Research Center for Bioelectrics at Old Dominion University, will speak on “Gene Electrotransfer for the Enhanced Delivery of Immunomodulating Agents.” In this presentation, Dr. Heller will present data on electroporation and delivery of plasmids for cancer immunotherapy, a technology used in OncoSec’s ImmunoPulse therapy.

From 12:00 PM-12:30 PM PT, Adil Daud, M.D., clinical professor of medicine and dermatology and director of the melanoma program at the University of California, San Francisco, will speak on “Clinical Studies of Melanoma Therapy.” In this presentation, Dr. Daud will be reviewing previously presented interim data from OncoSec’s ongoing Phase II trial for metastatic melanoma for which he is principal investigator.

The DNA Vaccines Conference brings in an array of researchers from all corners of the world to present new cutting-edge discoveries in DNA vaccines that have never before been presented or published at any other meeting. For more information about the conference, please visit: www.bioconferences.com/conferences/dna/index.aspx

 

 


Real Time Web Analytics